arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IMMUCELL CORP /DE/

ICCC
$10.94 ▼ -0.03 (-0.27%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Bearish
auto_awesome

Analytical Summary

IMMUCELL CORP /DE/ faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $98.7M
Dividend Yield
Revenue Growth 4.3%
Op. Margin 6.0%
ROIC 4.6%
FCF / Share $0.14
Trailing P/E
Price / Book 3.7x
FCF Yield 1.2%
Debt / Equity 0.34
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$27.64M
↑ +4.3%
Net Income Profit after all expenses
$-1.04M
↑ +51.8%
Operating Margin Operating profit as % of sales
6.0%
↑ +196.4% 46th
FCF / Share Free cash flow per share
$0.14
↑ +1127.9%
Long-Term Debt Long-term obligations
$9.10M
↑ +0.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
37
Returns
39
Financial Health
65
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters